Search research articles
Contact Us
Filters
Showing results (1-10 of 151) with videos related to
Page
of 16
Sort By:
Expert Review of Anticancer Therapy
|
May 12, 2007
Novel inhibitors in the treatment of metastatic melanoma
Kevin Kalinsky, Frank G Haluska
Journal of Comparative Effectiveness Research
|
November 19, 2013
Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting
Kevin Kalinsky, Dawn L Hershman
Expert Opinion on Biological Therapy
|
October 22, 2020
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan
Julia E McGuinness, Kevin Kalinsky
Future Oncology (London, England)
|
March 21, 2019
Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer
Joyce O'Shaughnessy, Virginia Kaklamani, Kevin Kalinsky
Therapeutic Advances in Medical Oncology
|
March 31, 2022
Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?
Caitlin Taylor, Jane Meisel, Kevin Kalinsky
Cancers
|
December 11, 2022
Trop-2 as a Therapeutic Target in Breast Cancer
Elizabeth Sakach, Ruth Sacks, Kevin Kalinsky
Seminars in Oncology
|
December 18, 2007
The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications
Frank Haluska, Trevor Pemberton, Nageatte Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2020
Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?
Anne H Blaes, Evidio Domingo-Musibay, Kevin Kalinsky
Breast Cancer Research and Treatment
|
July 2, 2021
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer
Matthew R Kearney, Julia E McGuinness, Kevin Kalinsky
British Journal of Clinical Pharmacology
|
May 28, 2016
AKT in cancer: new molecular insights and advances in drug development
Prabhjot S Mundi, Jasgit Sachdev, Carolyn McCourt, et al.
Page
of 16
Search research articles
Search
Showing results (1-10 of 151) with videos related to
Sort By:
Page
of 16
Expert Review of Anticancer Therapy
|
May 12, 2007
Novel inhibitors in the treatment of metastatic melanoma
Kevin Kalinsky, Frank G Haluska
Journal of Comparative Effectiveness Research
|
November 19, 2013
Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting
Kevin Kalinsky, Dawn L Hershman
Expert Opinion on Biological Therapy
|
October 22, 2020
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan
Julia E McGuinness, Kevin Kalinsky
Future Oncology (London, England)
|
March 21, 2019
Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer
Joyce O'Shaughnessy, Virginia Kaklamani, Kevin Kalinsky
Therapeutic Advances in Medical Oncology
|
March 31, 2022
Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?
Caitlin Taylor, Jane Meisel, Kevin Kalinsky
Cancers
|
December 11, 2022
Trop-2 as a Therapeutic Target in Breast Cancer
Elizabeth Sakach, Ruth Sacks, Kevin Kalinsky
Seminars in Oncology
|
December 18, 2007
The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications
Frank Haluska, Trevor Pemberton, Nageatte Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2020
Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?
Anne H Blaes, Evidio Domingo-Musibay, Kevin Kalinsky
Breast Cancer Research and Treatment
|
July 2, 2021
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer
Matthew R Kearney, Julia E McGuinness, Kevin Kalinsky
British Journal of Clinical Pharmacology
|
May 28, 2016
AKT in cancer: new molecular insights and advances in drug development
Prabhjot S Mundi, Jasgit Sachdev, Carolyn McCourt, et al.
Page
of 16